Clinical Trial Update: A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for Sativex Oromucosal Spray in relieving uncontrolled persistent pain in advanced cancer patients completed with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Pain

Drugs mentioned

• Sativex (nabiximol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Pain, Advanced Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-04-23